e-learning
resources
London 2016
Monday, 05.09.2016
Rifampicin resistance, MDRTB, and new drug treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate
Anna Starshinova (St-Peterburg, Russian Federation), Anna Starshinova, Maria Pavlova, Evgenia Istomina, Ekaterina Belaeva, Irina Chernokhaeva, Peter Yablonskiy
Source:
International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Session:
Rifampicin resistance, MDRTB, and new drug treatments
Session type:
Poster Discussion
Number:
1917
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Anna Starshinova (St-Peterburg, Russian Federation), Anna Starshinova, Maria Pavlova, Evgenia Istomina, Ekaterina Belaeva, Irina Chernokhaeva, Peter Yablonskiy. Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate. Eur Respir J 2016; 48: Suppl. 60, 1917
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Clinical experience of clofazimine in the treatment of MDR-TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
Failure predictors when treating MDR-TB
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Healing predictors when treating MDR-TB
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
Availability of PCR for second-line drugs in Europe
Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment
Year: 2016
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Current status of fluoroquinolone use for treatment of tuberculosis in Korea
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
MDR-TB treatment outcomes in HIV positive patients
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014
Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures?
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Spectrum of adverse drug reactions during MDR TB treatment
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Could side effects of MDR-TB treatment change the outcome of the disease?
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Impact of social support programme on MDR-TB patients' treatment outcomes
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Use of delamanid for M/XDR-TB treatment under programmatic conditions in Latvia
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept